AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00895453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: itraconazole
Description: 6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid)
Study NCT00895453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactobacillus gasseri
Description: Lactobacillus vaginal tablets monthly given through 6 days
Study NCT00895453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)
Description: CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
Study NCT04371692 — intervention group
Intervention type: OTHER
Intervention: self-administered questionnaire
Description: Every weeks during 2 months, clinical and occupational questionnaire are performed among a cohort of HCW exposed to covid occupational exposure
Study NCT04371692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-Cov2 testing
Description: Every weeks during 2 month, SARS-Cov2 RT-PCR, serological testing are performed among a cohort of HCW exposed to covid occupational exposure
Study NCT02304289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Oral Artesunate once-daily for 14 days, dose-escalation
Study NCT04439318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study NCT01918059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Adhesive skin closure
Description: The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with tissue adhesive (octyl-2-cyanoacrylate).
Study NCT01918059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Absorbable suture skin closure
Description: The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with absorbable sutures (surgical gut).
Study NCT01918059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-absorbable suture skin closure
Description: The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with either non-absorbable sutures (6-0 polypropylene).
Study NCT03222024 — intervention group
Intervention type: OTHER
Intervention: routine medical care
Description: This is an observational study for clinical course and outcomes of severe ischaemic stroke; therefore, interventions are prescribed by responsible doctors based on patients' clinical conditions, which is not interfered by current study
Study NCT02474953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Proprietary Curcumin Formulation
Study NCT02474953 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Unformulated Comparator Curcumin Product
Study NCT04597073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Initial Periodontal Therapy
Description: Oral hygiene education, including the use of toothbrushes and dental floss and/or interproximal brushes, was given to them. After one week Chronic Periodontitis group received nonsurgical periodontal therapy consisting of scaling and root planing (quadrant by quadrant) using manual scalers and curettes under local anesthesia. No antibiotics or any medications were prescribed during the treatment. Periodontal treatment was performed by the same investigator
Study NCT00761527 — intervention group
Intervention type: DRUG
Intervention: Desloratadine Syrup
Description: Desloratadine (Aerius) Syrup;~Dose selection was based upon the age of the participant, and the timing of dose for each participant was once daily (QD) as described in the Product Insert for 14 days:~* Children 6 through 11 years of age, 5 mL (milliliters) of Aerius Syrup (2.5 mg \[milligrams\] of desloratadine)~* Children 1 through 5 years of age, 2.5 mL of Aerius Syrup (1.25 mg of desloratadine)~* Children 6 months to 11 months of age, 2 mL of Aerius Syrup (1 mg of desloratadine)
Study NCT02113358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous colloid bolus with Voluven
Study NCT02113358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous colloid bolus with Voluven
Study NCT04036929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen-bazedoxifene
Description: Conjugated estrogens 0.45 mg-bazedoxifene acetate 20 mg.
Study NCT04036929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet
Study NCT00051922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PolyEnv1
Description: Recombinant vaccinia virus vaccine
Study NCT03036618 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinoa
Description: Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
Study NCT03036618 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat
Description: Test wheat bread roll (approximately 160g weight) without quinoa.
Study NCT03489928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Misoprostol
Description: Prostaglandin E1 - 100ug tablet, divided in half by pharmacy staff to be administered by mouth.
Study NCT03489928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaginal Misoprostol
Description: Prostaglandin E1 - 100ug oral tablet, divided in quarters by pharmacy staff, vaginal placement of one or two quarters as needed every 6 hours
Study NCT03489928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: Prostaglandin E2 - 1-2mg gel manufactured for vaginal use; placed vaginally every 6 hours as needed.
Study NCT03942939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Robotic-Assisted Total Knee Arthroplasty with a short tourniquet time
Description: Primary Robotic-Assisted Total Knee Arthroplasty with a short tourniquet time. Short tourniquet time is defined in this study as the release of the tourniquet after the initial exposure, resulting in a total tourniquet time of only 10-15 minutes.
Study NCT03942939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary Robotic-Assisted Total Knee Arthroplasty with the use of a tourniquet
Description: Primary Robotic-Assisted Total Knee Arthroplasty with the use of a tourniquet
Study NCT01219062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: periarticular infiltration with 0.25% Bupivacaine for 20 ml.
Study NCT01219062 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: the patients will be received spinal anesthesia with 0.5% Isobaric Bupivacaine and postoperative pain control by intravenous (IV) Patient - control Analgesia (PCA)
Study NCT01219062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
Study NCT02339792 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: E-learning
Description: e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
Study NCT01894438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean lifestyle
Description: Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean lifestyle group culinary practices, seasonality, and locality of food products, socialization during meals, rest during the day, as well as the adoption of an active living will be additionally addressed.
Study NCT01894438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean diet group, all food groups of the Mediterranean diet will be targeted.
Study NCT03309930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehension Acquired Brain Injury
Description: For study 1 participants will be exposed to 3 conditions as stated in previous descriptions and will last 1 to 2 sessions. Study 2 will begin with 1 session with the researcher lasting about 30 minutes. Then participants will be asked to complete practice at home for about 15 minutes each day for 2 weeks using a computer/iPad. Study 2 Post Testing and Maintenance Sessions 1 and 2: approximately 60 minutes per session.
Study NCT00541853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: Candesartan upto 8mg
Study NCT00541853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan and Cilnidipine
Description: Candesartan upto 8mg per day and Cilnidipine upto 20mg per day
Study NCT00541853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan plus non-CCB agents
Description: Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI
Study NCT04328142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Qigong group
Description: Traditional Chinese Medicine exercise programme
Study NCT04328142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy exercise programme
Study NCT03969186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Telehealth intervention monitoring weight and medication adherence accompanied by a weekly phone call to monitor symptoms.
Study NCT03565835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue
Study NCT03565835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Abiraterone Acetate with Prednisone and with Discontinuation of GnRH Analogue
Study NCT04248088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gentle Stretching and Education
Description: 60 minutes of gentle stretching twice weekly for 6 months
Study NCT01686282 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried Blueberry Powder
Description: 8 weeks of freeze-dried taken in two doses of 22g each per day.
Study NCT01686282 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 weeks of freeze-dried taken in two doses of 22g each per day.
Study NCT04458753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee focused exercises
Description: Strengthening of quadriceps Stretching of calf and Hamstring muscles
Study NCT04883034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adductor canal block in outpatient clinic
Description: perform adductor canal block in outpatient clinic for patient post total knee arthroplasty
Study NCT04883034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Analgesics, etoricoxibe
Description: anaelgetic oral intake
Study NCT02859441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injections of the commercially-available 10 mg/mL formulation of ranibizumab. Ranibizumab is formulated as a sterile solution (pH 5.5) with histidine, trehalose and polysorbate 20. The vial contains no preservative. Each vial contains 0.5 mL of 10 mg/mL ranibizumab aqueous solution. The intravitreal injection volume of ranibizumab is 50 microliter, which correlates to 0.5 mg of dry ranibizumab.
Study NCT02859441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E10030
Description: E10030 is not a commercially available drug product, and will be provided by Ophthotech Corp. The drug product is provided as a sterile aqueous solution of E10030 at a concentration of 30 mg (oligo weight)/mL. The solution contains monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate as buffering agents as well as sodium chloride as a tonicity adjuster. The intravitreal injection volume of E10030 is 50 microliter, which correlates to 1.5 mg of dry E10030.
Study NCT04458753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee focused exercises
Description: Strengthening of quadriceps Stretching of calf and Hamstring muscles
Study NCT04426565 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: motivational enhancement interview
Description: Motivational interviewing is supported by over 200 randomized controlled trials across a range of target populations and behaviors including substance abuse, health-promotion behaviors, medical adherence, and mental health issues.
Study NCT00303719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: ATG dose is 15 mg/kg intravenous (IV) every 12 hours for 6 doses on days -6, -5, and -4.~Those that should/will receive ATG in the preparative regimen:~* Related donor recipients who have not had exposure to combination chemotherapy in the 6 months preceding transplant should~* Unrelated donor recipients who have not had exposure to combination chemotherapy in the 3 months preceding transplant will~* Unrelated donor recipients who have had only a single induction cycle for the treatment of ALL/AML or MDS or CML blast crisis should~* Recipients with a prior autologous transplant in the year prior to second transplant do not require ATG.
Study NCT00913926 — intervention group
Intervention type: DRUG
Intervention: E2/LNG oral (Wellnara, BAY86-5029)
Description: Patients in daily life treatment receiving Wellnara according to local drug information.
Study NCT01900743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.
Study NCT01900743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
Study NCT00659230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepicastat
Description: 100-800mg
Study NCT00659230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100-800mg placebo
Study NCT00861471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: One treatment cycle is defined as 21 days.~Docetaxel: 70 mg/m\^2 (60 mg/m\^2 was tested in Phase I as well), Intravenous, every 21 days.
Study NCT00861471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: One treatment cycle is defined as 21 days.~Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days.
Study NCT00669383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone
Description: 12 mg IM q 24 hours x 2 doses
Study NCT00669383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo IM q 24 hours x 2 doses
Study NCT03742453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: contrast-enhanced ultrasound
Description: CEUS is performed using SonoVue (Bracco, Milan, Italy) intravenous administration in eligible participants within a month before/after EOB-MRI.
Study NCT03742453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EOB-MRI
Description: EOB-MRI is performed using standard dose of hepatocyte specific contrast media (primovist or eovist) according to standard protocol of our institution.
Study NCT04667546 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Survey
Description: Patients or their parents will complete a survey at D2, D5, D10 and D28 to assess the presence or absence of a symptom
Study NCT02997982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir 500Mg Tablet
Description: Valaciclovir treatment (oral, 500 mg tablets). First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.
Study NCT00269633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue Light Box 467 nm
Description: 467 nm Blue LED Light
Study NCT00269633 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Red Light Box 657 nm
Description: 657 nm Red LED Light
Study NCT02419820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD791
Description: Temanogrel
Study NCT04426565 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: the individual psychotherapy
Description: It has been demonstrated to be an effective treatment for depression and has been modified to treat other psychiatric disorders such as substance use disorders and eating disorders. It is incumbent upon the therapist in the treatment to quickly establish a therapeutic alliance with positive countertransference of warmth, empathy, affective attunement and positive regard for encouraging a positive transferential relationship, from which the patient is able to seek help from the therapist despite resistance.
Study NCT04426565 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: the group psychotherapy
Description: Group psychotherapy is a key component of milieu therapy in a therapeutic community. The total environment or milieu is regarded as the medium of therapy, all interactions and activities regarded as potentially therapeutic and are subject to exploration and interpretation, and are explored in daily or weekly community meetings. A form of group therapy has been reported to be effective in psychotic adolescents and recovering addicts.
Study NCT04426565 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: the family therapy
Description: According to a 2004 French government study conducted by French Institute of Health and Medical Research, family and couples therapy was the second most effective therapy after Cognitive behavioral therapy. The study used meta-analysis of over a hundred secondary studies to find some level of effectiveness that was either proven or presumed to exist. Of the treatments studied, family therapy was presumed or proven effective at treating schizophrenia, bipolar disorder, anorexia and substance dependence.
Study NCT03568357 — intervention group
Intervention type: PROCEDURE
Intervention: Reoxygenation
Description: After one minute of full bypass, fraction of inspired oxygen (FiO2) in conservative group was increased at increments of 0.1 per minute to reach an FiO2 target of 40% that was adjusted to maintain an arterial PO2 in the range of 250 mm Hg or less during the bypass, while FiO2 in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 80% adjusted to maintain PO2 in the range of 300 mm Hg or more, on the basis of arterial PO2 level measured via a point of care blood gas analyzer.
Study NCT02245256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex
Description: infusion of 0.1mcg/kg/hr of precedex
Study NCT02245256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: placebo
Study NCT02867540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI enterography
Study NCT02410499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MLN1202 Placebo
Description: MLN1202 placebo-matching solution for SC injection
Study NCT02410499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202
Description: MLN1202 solution for SC injection
Study NCT03068975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alvimopan
Description: Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive Alvimopan ( post operative dose only) and will monitor for post operative ileus.
Study NCT03068975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive the Placebo Pill (post operative dose only) and will monitor for post operative ileus.
Study NCT03210610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: colchicine level measurement
Description: levels of colchicine will be measured in FMF patients taking colchicine
Study NCT02602587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: additional samples of blood in acts planned in the prognostic or follow-up protocols.
Study NCT02602587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow sample
Description: additional bone marrow sample in acts planned in the prognostic or follow-up protocols.
Study NCT01516957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 827 140
Description: 140 mg AMG 827 SC (subcutaneous)
Study NCT01516957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC (subcutaneous)